Everything below concerns GHS-R1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-18. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
== Side effects == Most frequent side effects are nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre. Vasospasms with serious consequences such as myocardial infarction and stroke that have been reported in connection with the puerperium, appear to be extremely rare events. Peripheral vasospasm (of the fingers or toes) can cause Raynaud's phenomenon. Bromocriptine use has been anecdotally associated with causing or worsening psychotic symptoms (its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine receptors). It should be understood, however, that the greater affinity bromocriptine and many similar antiparkinson's drugs have for the D2S receptor form (considered to be mostly present at inhibitory D2 autoreceptor locatations) relative to the D2L form, sufficiently low partial agonist activity (i.e. where a molecule binding to a receptor induces limited effects while preventing a stronger ligand like dopamine from binding), and, possibly, the functional selectivity of a particular drug may generate antidopaminergic effects that are more similar than oppositional in nature to antipsychotics. Pulmonary fibrosis has been reported when bromocriptine was used in high doses for the treatment of Parkinson's disease.
Hydra vulgaris, (previously Hydra magnipapillata), a model hydrozoan (2010) Nematostella vectensis, a model sea anemone (starlet sea anemone) (2007) Aiptasia pallida, a sea anemone (2015) Renilla muelleri, an octocoral (2017, 2019) Stylophora pistillata, a coral (2017) Aurelia aurita, moon jellyfish (2019) Clytia hemisphaerica, Hydrozoan jellyfish (2019) Myxobolus honghuensis (2022) Nemopilema nomurai, Nomura jellyfish (2019) Rhopilema esculentum, Flame jellyfish (2020) Cassiopea xamachana (Scyphozoa) (2019) Alatina alata (Cubozoa) (2019) Calvadosia cruxmelitensis (Staurozoa) (2019) Dendronephthya gigantea, an octocoral (2019) Acropora acuminata (2020) Acropora awi (2020) Acropora cytherea, Table coral (2020) Acropora digitifera, a coral (2011) Acropora echinata (2020) Acropora florida, branching staghorn coral(2020) Acropora gemmifera (2021) Acropora hyacinthus, Brush coral (2020) Acropora intermedia, Noble Staghorn Coral (2020) Acropora microphthalma (2020) Acropora muricata, Staghorn coral (2020) Acropora nasta, branching staghorn coral (2020) Acropora pulchra (2025) Acropora selago, Green Selago Acropora (2020) Acropora tenuis, Purple Tipped Acropora (2020) Acropora yongei ,Yonge's staghorn coral (2020) Corallium rubrum, Precious coral (2024) Astreopora myriophthalma, Porous star coral (2020) Lophelia pertusa, Deepwater White Coral (2023) Montipora cactus (2020) Montipora capitata, Rice coral (2022) Montipora efflorescens, Velvet coral (2020) Orbicella faveolata, mountainous star coral (2016) Paragorgia papillata, Bubble-gum coral (2025) Pocillopora acuta, Hosoeda Hanayasai coral (2022) Pocillopora damicornis, cauliflower coral (2018) Pocillopora meandrina, Cauliflower coral (2022) Porites astreoides, Mustard hill coral (2022) Porites compressa, Finger coral (2022)
In pharmacology and pharmaceutics, a prototype drug is an individual drug that represents a drug class – group of medications having similar chemical structures, mechanism of action and mode of action. Prototypes are the most important, and typically the first developed drugs within the class, and are used as a reference to which all other drugs are compared.
RCH(NHP)CO2H + R'CH(NH2)CO2CH3 → RCH(NHP)C(O)NH(CHR')CO2CH3 + H2O Subsequent to this coupling reaction, the amine protecting group P and the ester are converted to the free amine and carboxylic acid, respectively. For many amino acids, the ancillary functional groups are protected. The condensation of the amine and the carboxylic acid to form the peptide bond generally employs coupling agents to activate the carboxylic acid. The Bergmann azlactone peptide synthesis is a classic organic synthesis for the preparation of dipeptides.
Sources: en.wikipedia.org
=== Division of Israel and Judah === The monarchic state was divided into two states, Israel and Judah, due to civil and religious disputes. Eventually, Israel and Judah met their demise after the Assyrian and Babylonian invasions respectively. According to the Biblical prophets, these invasions were divine judgements for religious apostasy and corrupt leadership. This period is covered by 1 Kings 12 to 2 Kings 25 or alternatively, 2 Chronicles 10 to 2 Chronicles 36. The Book of Jonah narrates the prophet Jonah going to the Neo-Assyrian Empire to deliver a divine message.
When King Ferdinand II enacted a liberal constitution in January 1848 in the wake of popular demonstrations, many southern liberals were elected in the parliamentary elections. However, on 5 May 1848, in a coup d'état, he dissolved Parliament and bombed rebellious Naples, causing more than 1,000 deaths. Insurrectional committees arose in Calabria: the most organized were from Cosenza and Catanzaro, which raised arms, funds and volunteers to resist. Despite their efforts, divisions over how to conduct military operations compromised their efforts and the Calabrian insurgents were dispersed by the arrival of 5,000 Bourbon soldiers under Generals Nunziante and Busacca. Political repression followed the defeat, manifested in death sentences or life in prison (some in absentia) of the major leaders. This caused the final rift between the Bourbon monarchy and the liberal bourgeoisie, which soon joined the Italian unification cause. Counting on this connection. Giuseppe Garibaldi landed on the Calabrian coast, at Melito di Porto Salvo, on 19 August 1860, after conquering Sicily. The Calabrian insurgents led by Agostino Plutino from Reggio backed the Garibaldi volunteers. With their aid, at the 21 August Battle of Piazza Duomo, Garibaldi conquered Reggio Calabria. He disarmed as many as 12,000 of Colonel Vial's men at Soveria Mannelli. Garibaldi's army then marched on Naples, entering on September 6. The Battle of the Volturno (26 September-2 October 1860) averted the Bourbon reconquest of Naples.
Sam Chun Dang Pharm Co., Ltd. (Korean: 삼천당제약; Hanja: 三千堂製藥; RR: Samcheondang jeyak), commonly abbreviated as SCD, is a South Korean pharmaceutical company engaged in the development, manufacturing, and sale of prescription medicines. Founded in 1943, the company is headquartered in Seocho-gu, Seoul, with manufacturing operations at the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. SCD is listed on the Korea Exchange (KRX: 000250). The company is best known for its ophthalmic products, which accounts for approximately half of its total revenues, and has attracted attention for its development of an aflibercept biosimilar (SCD411) and an oral semaglutide generic.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.